Search clinical trials for: Fluticasone furoate/ Vilanterol 100 mcg/25 mcg

Total 911 results

GlaxoSmithKline

Completed

An Efficacy and Safety Study of Fluticasone Furoate/Vilanterol (FF/VI) 200/25 Microgram (mcg) , FF/VI 100/25 mcg, and FF 100 mcg in Adults and Adolescents With Persistent Asthma.

Asthma

United States, Argentina, Germany, Romania, Russian Federation, Ukraine, Chile, Sweden, Mexico, Netherlands, Poland
GlaxoSmithKline

Completed

Cross-Over Study in Subjects With COPD, Evaluating Lung Function Response After Treatment With Once Daily Umeclidinium 62.5mcg, Vilanterol 25mcg, and Umeclidinium/Vilanterol 62.5/25mcg

Pulmonary Disease, Chronic Obstructive

Germany, Estonia
GlaxoSmithKline

Withdrawn

A Study Comparing the Closed Triple Therapy, Open Triple Therapy and a Dual Therapy for Effect on Lung Function in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Canada, Germany
GlaxoSmithKline

Completed

Crossover Study Comparing Fluticasone Furoate (FF)/Vilanterol (VI) Once Daily Versus Fluticasone Propionate (FP) Twice Daily in Subjects With Asthma and Exercise-Induced Bronchoconstriction (EIB)

Asthma

United States, Canada
Sunovion Respiratory Development Inc.

Completed

A Study of the Efficacy and Safety of EP-101 ( (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease (GOLDEN-2)

COPD

United States
GlaxoSmithKline

Completed

Dose Proportionality Study: Blood Levels of Fluticasone Furoate (FF) and Vilanterol (VI) Following Different Doses of FF/VI Via an Inhaler

Asthma

United Kingdom
GlaxoSmithKline

Completed

A Phase IIA FF/VI Study to Measure FeNO in Asthmatic Patients.

Asthma

New Zealand
GlaxoSmithKline

Completed

A Study To Investigate The Effect Of Inhaling A Single Dose Of GW642444M In Asthmatic Patients

Pulmonary Disease, Chronic Obstructive

United Kingdom
GlaxoSmithKline

Completed

A Study to Compare the Efficacy and Safety of Fluticasone Furoate (FF) 100 mcg Once Daily With Fluticasone Propionate (FP) 250 mcg Twice Daily (BD) and FP 100 mcg BD in Well-controlled Asthmatic Japanese Subjects

Asthma

Japan
National Institute of Respiratory Diseases, Mexico

Completed

Efficacy and Safety of ICS/LABA vs. LAMA/LABA in Patients With Different COPD Phenotypes.

COPD

Mexico
GlaxoSmithKline

Completed

A Cross-Over Study to Evaluate Lung Function Response After Treatment With Umeclidinium (UMEC) 62.5 Micrograms (mcg), Vilanterol (VI) 25 mcg, and Umeclidinium/Vilanterol (UMEC/VI) 62.5/25 mcg Once-Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Ukraine, Slovakia
GlaxoSmithKline

Completed

Pharmacokinetics Of Umeclidinium and Vilanterol in Healthy Chinese, a Randomized, Open Label, 3 Crossover Study.

Pulmonary Disease, Chronic Obstructive

China
National Institute of Allergy and Infectious Diseases...
National Institutes of Health (NIH); Department of Health and Human Services

Suspended

A Clinical Trial to Evaluate Safety, Tolerability, and Immunogenicity of Adjuvanted HIV-1 Fusion Peptide Conjugate Vaccine Alone or in Prime-Boost Regimens With Adjuvanted HIV-1 Envelope Trimer 4571 and HIV-1 Trimer 6931 Vaccines in Healthy Adults

HIV

United States
GlaxoSmithKline

Completed

A Phase III Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination (FDC) of Fluticasone Furoate+Umeclidinium Bromide+Vilanterol (FF/UMEC/VI) With the FDC of FF/VI in Subjects With Inadequately Controlled Asthma

Asthma

Australia, United States, Argentina, Canada, Germany, Japan, Korea, Republic of, Romania, Russian Federation, Spain, South Africa, Netherlands, Poland, Italy, United Kingdom
Boehringer Ingelheim

Completed

A Study in the US Based on Pharmacy and Medical Claims That Compares How Well Stiolto® and Trelegy® Work in People With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States
Protalex, Inc.

Completed

Safety Study of PRTX-100 With Methotrexate or Leflunomide to Treat Active Rheumatoid Arthritis (SPARTA)

Arthritis, Rheumatoid

United States
DBV Technologies

Completed

Efficacy and Safety of Several Doses of Viaskin Peanut in Adults and Children With Peanut Allergy (VIPES)

Peanut Allergy

United States, Netherlands, France, Canada, Poland
Alexza Pharmaceuticals, Inc.

Completed

Staccato Fentanyl Single and Multidose PK

Breakthrough Pain

United States
Janssen Pharmaceutical K.K.

Completed

Safety, Pharmacokinetics, and Pharmacodynamics Study of Single Dose of CNTO 3649 in Healthy Adult Men and Multiple Doses of CNTO 3649 in Participants With Type 2 Diabetes Mellitus

Healthy | Diabetes Mellitus, Type 2

Japan
AstraZeneca

Completed

A Comparison of Symbicort® Single Inhaler Therapy and Conventional Best Practice for the Treatment of Persistent Asthma (PASSION)

Asthma

Turkey
Sunovion Respiratory Development Inc.

Completed

A Dose-Range Finding Study of SUN-101 in Subjects With Moderate to Severe COPD (GOLDEN 6)

COPD

United States
Merck KGaA, Darmstadt, Germany

Terminated

Sprifermin (AS902330) in Cartilage Injury Repair (CIR)

Isolated Cartilage Injury of the Knee

Germany
GlaxoSmithKline

Completed

A Study to Compare the Impact of Fulticasone Furoate/Vilanterol vs. Tiotropium on Arterial Stiffness in COPD

Pulmonary Disease, Chronic Obstructive

Argentina, France, Germany, Russian Federation, Ukraine, Italy, Norway
Sandoz

Completed

A Study Comparing Two Fluticasone Furoate Nasal Sprays in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis

Rhinitis, Allergic, Seasonal

United States
Hawaii Pacific Health

Recruiting

Tension Versus no Tension With Foley Bulb Induction

Induction of Labor Affected Fetus / Newborn

United States
Sunovion Respiratory Development Inc.

Completed

Efficacy and Safety Trial of 12 Weeks of Treatment With Nebulized SUN-101 in Patients With COPD (GOLDEN-4) (GOLDEN-4)

Chronic Obstructive Pulmonary Disease | COPD

United States
Organon and Co

Completed

A Study of Mometasone Furoate Metered Dose Inhaler in Children With Persistent Asthma (P04223)

Asthma
Organon and Co

Completed

A Serious Asthma Outcome Study With Mometasone Furoate/Formoterol Versus Mometasone Furoate in Asthmatics 12 Years and Over (P06241) (SPIRO)

Asthma
Milton S. Hershey Medical Center

Completed

Step-up Yellow Zone Inhaled Corticosteroids to Prevent Exacerbations (STICS)

Asthma

United States
Novartis Pharmaceuticals

Terminated

Study of Safety of Foradil in Patients With Persistent Asthma

Persistent Asthma

United States
GlaxoSmithKline

Completed

Safety, Blood Levels and Effects of GW642444

Pulmonary Disease, Chronic Obstructive

United Kingdom
Mylan Pharmaceuticals Inc

Terminated

Study of the Effect of Clinical Procedures on Drug Delivery of Mylan Fentanyl Transdermal System 25 µg/hr and Duragesic® 25 µg/hr

Healthy

United States
Organon and Co

Completed

Asthma Study Comparing Anti-Inflammatory Effects of 3 Doses of Mometasone Furoate/Formoterol Fumarate and Medium Dose Mometasone Furoate (Study P05122 AM1)(COMPLETED)

Asthma | Airway Inflammation
DBV Technologies
University Hospital, Geneva

Completed

Viaskin Pertussis Vaccine Trial

Whooping Cough

Switzerland
GlaxoSmithKline

Completed

Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

United States, Argentina, Japan, Poland, Romania, Russian Federation, Spain, Ukraine, Germany, Taiwan, Bulgaria, Hungary, France, Philippines, South Africa, Thailand, Israel, Korea, Republic of, Australia, Mexico, Slovakia, United... and more
MC2 Therapeutics

Recruiting

The MC2-25 Cream in Subjects wITh CHronic KIdNEy Disease-aSsociated prurituS (ITCHINESS) Trial (ITCHINESS)

Chronic Kidney Disease-associated Pruritus

United Kingdom
Chiesi Farmaceutici S.p.A.

Withdrawn

TRIMBOW® and RELVAR® on Lung Stiffness Reduction Assessed Through Forced Oscillation Technique in Patients With COPD

COPD
University of Oxford

Completed

A BCG Challenge Model Study to Assess Anti-mycobacterial Immunity Induced by BCG and a Candidate TB Vaccine, MVA85A

Tuberculosis

United Kingdom
St. Joseph's Healthcare Hamilton
GlaxoSmithKline

Completed

Relative Potency of Inhaled Corticosteroids

Asthma | Chronic Obstructive Pulmonary Disease (COPD)

Canada
Sandoz

Completed

A Study Comparing the Clinical Equivalence of Two Mometasone Nasal Sprays in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis

Rhinitis, Allergic, Seasonal

United States
Amneal Pharmaceuticals, LLC
Novum Pharmaceutical Research Services

Completed

Study to Compare the Therapeutic Equivalence of Mometasone Furoate Nasal Spray, 50 mcg With Nasonex Nasal Spray in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis

Seasonal Allergic Rhinitis

United States
GlaxoSmithKline

Completed

A Four-way Crossover, Single and Repeat Dose Study to Determine the Dose Proportionality and Absolute Bioavailability of Fluticasone Furoate Inhalation Powder Administered by Novel Dry Powder Inhaler (NDPI)

Asthma

Netherlands
Mylan Pharmaceuticals Inc

Completed

Bioequivalence and Wear Study of Mylan Fentanyl Transdermal System 25 µg/h and Mylan Fentanyl Transdermal System

Healthy

United States
GlaxoSmithKline

Completed

A Study to Assess the Bronchodilator Effect of a Single Dose of Fluticasone Furoate (FF)/ Vilanterol (VI) 100/25 Micrograms (mcg) Combination When Administered in Adult Patients With Asthma

Asthma

New Zealand
Morten Hostrup, PhD

Recruiting

U-LABA/ICS Effects on Exercise Performance, Vilanterol

Exercise Performance

Denmark
GlaxoSmithKline

Completed

An Efficacy and Safety Study of Fluticasone Furoate/Vilanterol 100/25 Microgram (mcg) Inhalation Powder, Fluticasone Propionate/Salmeterol 250/50 mcg Inhalation Powder, and Fluticasone Propionate 250 mcg Inhalation Powder in Adults and Adolescents With Persistent Asthma

Asthma

United States, Argentina, Germany, Korea, Republic of, Romania, Russian Federation, Spain, Netherlands, Mexico, Brazil, Chile, Czechia
Novartis Pharmaceuticals

Completed

A Study to Assess the Effect of QAW039 in Non-atopic Asthmatic Patients

Asthma

Germany, United States, Belgium, Colombia, Czech Republic, India, Korea, Republic of, Poland, Romania, South Africa
Brigham and Women's Hospital

Completed

Replication of the IMPACT COPD Trial in Healthcare Claims Data

COPD

United States
Hamilton Health Sciences Corporation
AstraZeneca

Completed

Does Fluticasone Propionate Reduce the Late Allergic Reaction When the Drug is Given Post-allergen?

Mild Intermittent Asthma

Canada
PATH Vaccine Solutions

Completed

Phase I Safety Trial of Streptococcus Pneumoniae Whole Cell Vaccine (SPWCV) + Alum in Healthy Adults

Pneumococcal Vaccines

United States

3

Subscribe